Literature DB >> 7860236

Phase II trial of piroxantrone in gastric carcinoma. A Southwest Oncology Group study.

A Hantel1, C Tangen, W L Gluck, J S Macdonald.   

Abstract

Twenty-one evaluable patients with advanced gastric adenocarcinoma were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. One objective response was seen for an overall response rate of 5% (95% confidence interval 0-24%). Toxicities of grade > or = 3 were primarily hematologic and seen in 13/21 patients. Piroxantrone has minimal activity against gastric adenocarcinoma and no further investigation of this agent on this schedule in this disease is recommended.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7860236     DOI： 10.1007/bf00874449

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  7 in total

1.  Cancer statistics, 1994.

Authors:  C C Boring; T S Squires; T Tong; S Montgomery
Journal:  CA Cancer J Clin       Date:  1994 Jan-Feb       Impact factor: 508.702

2.  5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.

Authors:  H D Showalter; J L Johnson; L M Werbel; W R Leopold; R C Jackson; E F Elslager
Journal:  J Med Chem       Date:  1984-03       Impact factor: 7.446

3.  Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.

Authors:  W R Leopold; J M Nelson; J Plowman; R C Jackson
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

4.  Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.

Authors:  F J Panettiere; C Haas; B McDonald; J J Costanzi; R W Talley; J Athens; N Oishi; L K Heilbrun; T T Chen
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

5.  Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.

Authors:  A Hantel; R C Donehower; E K Rowinsky; E Vance; B V Clarke; W P McGuire; D S Ettinger; D A Noe; L B Grochow
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

6.  A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study.

Authors:  T R Jenkins; C Tangen; J S Macdonald; G Weiss; R Chapman; A Hantel
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

7.  Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria.

Authors:  S Green; G R Weiss
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.